AAVXF:OTCMKTS
Abivax SA
USD 139.00
0.00%
(0.00) 1H
9 Jul, 9:30:01 PG GMT-4 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk AAVXF...
Permodalan Pasaran
7.20B
Purata volum
0.00
Volum
0.00
tgi 52 mgu
USD 139.00
rdh 52 mgu
USD 71.26
Beta
2.98
Syer tertunggak
87.53J
Bilangan pekerja
98
Permodalan Pasaran
7.20B
Purata volum
0.00
Volum
0.00
tgi 52 mgu
USD 139.00
rdh 52 mgu
USD 71.26
Beta
2.98
Syer tertunggak
87.53J
Bilangan pekerja
98
Cerita berita
Daripada sumber web dan rakan kongsi berita
MarketBeat
·
3 hari lalu
Abivax (NASDAQ:ABVX) Stock Price Down 5.1% - Should You Sell?
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Perihal Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Pekerja98
Diasaskan4 Dis 2013
Ibu pejabat-
Sektor-
Laman webabivax.com